.png)
Launch Momentum Meets Market Reality: Managing the Levers for Success
- Jana Chisholm
- 5 hours ago
- 4 min read
Strong clinical performance remains essential—but sustained commercial success increasingly depends on how effectively companies align pricing, access, targeting, and competitive positioning
Executive Highlights
Galderma raised Nemluvio’s peak sales estimate to $4B+, driven by targeted positioning and strong access.
Obesity leaders Novo Nordisk and Eli Lilly are actively adjusting pricing, access, and supply strategy in real time.
Regeneron is defending Eylea by shifting differentiation toward durability and dosing convenience.
Increasingly, success depends on the ability to coordinate and flex multiple strategic levers, not optimize a single dimension.
Introduction
Commercial success in biopharma has always depended on more than clinical efficacy. Pricing, access, and physician adoption have long played central roles.
What has changed is how tightly these elements are now integrated—and how quickly companies must adjust them.
In today’s environment, strong clinical performance is necessary, but not sufficient. The most successful companies are those that can align and continuously rebalance:
Clinical differentiation
Pricing and contracting
Patient and provider targeting
Market access strategy
Recent launches and market developments illustrate how this more dynamic model is reshaping competitive outcomes.
Nemluvio: Targeted Positioning Drives Early Success
Galderma has doubled its peak sales estimate for Nemluvio (nemolizumab) to over $4 billion, reflecting strong early uptake.
Performance metrics:
2025 sales: $452M
Second-half contribution: $321M
Commercial coverage: ~85%
Market uptake:
35% share of new prurigo nodularis patients
8% share in atopic dermatitis
Atopic dermatitis represents a market roughly 10x larger than PN, providing significant runway for expansion.
Clinical and commercial positioning:
Rapid itch reduction
8-week dosing schedule
Focus on patients new to biologics
Rather than competing broadly with Dupixent, which generated $4.2B in Q4 sales, Nemluvio is being positioned selectively in patient segments where its profile is most compelling.
This reflects a broader trend: targeted positioning combined with early access strategy can drive meaningful share, even in established biologic markets.
Obesity Market: Growth Meets Real-Time Strategy Adjustment
The obesity market highlights how quickly commercial dynamics can evolve.
Novo Nordisk and Eli Lilly are not competing solely on efficacy. Instead, they are actively managing multiple levers simultaneously.
Clinical evolution:
Expanding into earlier lines of treatment
Developing oral formulations
Generating cardiovascular outcomes data
Pricing and access:
Adjusting pricing and rebates in response to competition
Expanding access through:
Employer coverage
Direct-to-consumer channels
Telehealth platforms
Supply and targeting:
Prioritizing high-value patient populations amid supply constraints
Scaling manufacturing investment
Market implications:
Consensus market size: ~$150B by 2032
Revised estimates: $80–120B, reflecting pricing pressure
This is not a static market. It is one where companies are continuously rebalancing pricing, access, and patient targeting in response to demand and competition.
India and the Global Pricing Signal
Global pricing dynamics are becoming increasingly interconnected, and India provides a clear example.
Market context:
~90 million diabetics
40+ manufacturers entering the GLP-1 space
Pricing comparison:
Generics: $13–18/month
Branded therapies: up to $175/month
This creates a potential downstream impact:
Pressure on global pricing benchmarks
Increased scrutiny from payers in developed markets
Risk of parallel pricing effects
At the same time, it introduces risks:
Overprescription
Variable product quality
Regulatory tightening
The result is a more complex global pricing environment where decisions in one market increasingly influence others.
Defending Market Leadership: Regeneron’s Eylea Strategy
Regeneron provides a clear example of how incumbents adapt to competitive pressure.
Facing competition from:
Vabysmo (longer-acting anti-VEGF)
Emerging therapies such as Axpaxli
Regeneron has shifted its strategy.
Key adjustment:
Development of high-dose Eylea enabling 8–16 week dosing intervals
This reframes competition:
From efficacy → to durability and convenience
At the same time, Regeneron is maintaining:
Strong payer relationships
Established physician adoption
This illustrates how companies can extend lifecycle value by evolving the clinical profile in response to competitive dynamics.
Clinical Strategy Is Now Market-Aware
Companies are also changing how they design clinical programs.
AstraZeneca has been particularly active in aligning trial design with downstream commercial needs.
Key approaches:
Biomarker-enriched patient populations
Use of real-world data to inform control arms
AI-supported trial design
These strategies aim to:
Improve probability of success
Strengthen differentiation
Support payer and physician adoption
Clinical development is increasingly being designed not just for approval—but for market positioning at launch.
Portfolio and Organizational Agility
Beyond individual products, companies are adjusting at the portfolio level.
Pfizer, for example, is restructuring following the decline of COVID-related revenues:
~13,000 roles eliminated over two years
Reallocation toward oncology and specialty care
This reflects a broader pattern:
Capital and talent shifting toward growth areas
Away from declining or volatile revenue streams
Success Increasingly Depends on Multi-Lever Agility
The most successful companies are no longer optimizing a single dimension of performance. Instead, they are managing a set of interconnected levers—and adjusting them dynamically as market conditions evolve.
These levers include:
Clinical differentiation (efficacy, durability, convenience)
Pricing and contracting strategy
Patient and provider targeting
Market access and reimbursement
Recent examples across the industry illustrate this shift:
Novo Nordisk and Eli Lilly are continuously adjusting pricing, access, and supply strategy in obesity
Regeneron has repositioned Eylea around durability and convenience
Galderma has driven Nemluvio uptake through targeted positioning and early access
The common theme is agility.
Companies that can rebalance these levers quickly—whether in response to pricing pressure, competitive entry, or shifting demand—are more likely to sustain growth.
The Convergence of Commercial Pressures
Across these examples, several patterns emerge:
Strong clinical performance → does not guarantee market success
Pricing pressure → reshapes market size and expectations
Global markets → influence local pricing and access decisions
Competitive positioning → requires continuous adjustment
Commercial success is no longer a fixed outcome at launch—it is an ongoing process of alignment and adaptation.
Outlook: Integrated Strategy as the Differentiator
The industry is moving toward a model where success depends on coordinated execution across all aspects of a product strategy.
Companies must align:
Clinical development
Pricing strategy
Market access
Competitive positioning
Those that can do so—and adjust quickly—will be best positioned to succeed.
🔑 Key Takeaway
The differentiator is no longer a single advantage—it is the ability to continuously align clinical profile, pricing, access, and targeting in response to a moving market.
